EditorialDr. Sasha Mallett, a physician battling her own immunodeficiencies, at home in Portland, Ore., March 1, 2022. (Amanda Lucier/The New York Times)
EditorialNurses at Houston Methodist Hospital administer a monoclonal antibody treatment to a COVID-19 patient, Laura Jeffery, 43, in Texas on Sept. 15, 2021. (Brandon Thibodeaux/The New York Times)
EditorialLouis Shantzek, a retiree who tried unsuccessfully to get a monoclonal antibody treatment after he tested positive for COVID, at home in Miami, Jan. 3, 2022. (Scott McIntyre/The New York Times)
EditorialChris Neblett generated low levels of antibodies after his third shot of the Pfizer vaccine, but it wasn’t until his fourth shot in November that his antibody levels matched a normal, healthy individual’s response. (Kristian Thacker/The New York Times)
EditorialA patient receives monoclonal antibodies in Anchorage, Alaska, on Oct. 25, 2021. Officials have been eager for a pill option. (Ash Adams/The New York Times)
EditorialMedical concierge services are offering coronavirus antibody tests as a perk, despite caveats about their usefulness. (Julia Dufosse/The New York Times)
EditorialHealth care workers administer antibody infusions at Houston Methodist in Texas on Wednesday, Sept. 15, 2021. (Brandon Thibodeaux/The New York Times)
EditorialMedical workers disinfect a room at the Children’s Hospital of San Antonio in Texas, after a patient with COVID-19 died, Aug. 10, 2021. (Meridith Kohut/The New York Times)
EditorialBernie Delgado prepares doses of the Pfizer-BioNTech vaccine in a cold storage room set up at Pratt & Whitney Stadium in East Harford, Conn., Feb. 4, 2021. (Christopher Capozziello/The New York Times)
EditorialBlood samples and trays of monoclonal antibody at Albert Einstein College of Medicine in the Bronx, Sept. 30, 2020. (Gabby Jones/The New York Times)
EditorialA pharmacist in Chandler, Ariz. prepares an injection during a trial for Regeneron’s antibody treatment, Aug. 12, 2020. (Adriana Zehbrauskas/The New York Times)
EditorialA patient sample awaits processing during an antibody trial in Mesa, Ariz. for Regeneron and Eli Lilly on Wednesday, Aug. 12, 2020. (Adriana Zehbrauskas/The New York Times)
EditorialA pharmacist in Chandler, Ariz. prepares an injection during a trial for Regeneron’s antibody treatment on Aug. 12, 2020. (Adriana Zehbrauskas/The New York Times)
EditorialPresident Donald Trump with Health and Human Services Secretary Alex Azar arrive during a news conference about the authorization of using convalescent plasma to treat coronavirus patients at the White House in Washington, Aug. 23, 2020. (Oliver Contreras/The New York Times)
EditorialA monoclonal antibody clinical trial site in Mesa, Ariz., is kept bare to ensure a faster disinfection process. (Adriana Zehbrauskas/The New York Times)
EditorialLab technicians collect blood samples for antibody testing from staff at a restaurant in Brooklyn, May 13, 2020. (Misha Friedman/The New York Times)
EditorialPastor Roberto Lopez, right, and the Rev. Carlos Osorio, second from left, distribute information as people line up to receive antibody testing at Christian Church John 3:16 in the Bronx on May 16, 2020. (Chang W. Lee/The New York Times)